GT Biopharma, Inc. (GTBP) Financials
Annual revenue, profitability and per-share results for GT Biopharma, Inc., as reported in SEC filings.
Revenue • FY2025
$0
Net income • FY2025
-$28.35M
▼ 115.4%YoY
Diluted EPS • FY2025
-$6.68
▲ 3.7%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $0 | -$28.35M | — | -$6.68 | — | — | — |
| FY2024 | $0 | -$13.16M | — | -$6.94 | — | — | — |
| FY2023 | $0 | -$7.6M | — | -$5.64 | — | — | — |
| FY2022 | $0 | -$20.88M | — | — | — | — | — |
Figures as reported in GT Biopharma, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a GTBP filing.
Get an email when GTBP files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.